Element Biosciences Raises $276M in Series C Financing

Element Biosciences

Element Biosciences, a San Diego, CA-based developer of a DNA sequencing platform, closed a $276m Series C financing. 

Backers included new investors Janus Henderson Investors, Logos Capital, Meritech Capital Partners, Counterpoint Global (Morgan Stanley), and T. Rowe Price and existing investors Fidelity Management & Research Company, Foresite Capital, JS Capital Management LLC,  RA Capital Advisors, and Venrock.

The company, which has raised approximately $400m in total funding, intends to use the capital to scale the commercial organization in anticipation of, as well as fund, the launch of its next-generation sequencing solution.

Led by Molly He, Ph.D., co-founder and chief executive officer, and John Stuelpnagel, DVM, chairman, Element Biosciences is a multi-disciplinary life science company currently focused on developing DNA sequencing technology for research and diagnostic markets, acceleration of scientific discoveries and broadening of the use of genomic medicine.